MSH3
Overview
MSH3 forms the MutSbeta heterodimer with MSH2 to recognize insertion-deletion loops during DNA mismatch repair. Biallelic MSH3 inactivation causes a microsatellite instability phenotype at dinucleotide repeats. MSH3 mutations are observed as co-mutations in BRAF fusion-positive colorectal cancer and in MSI-H prostate cancer.
Alterations observed in the corpus
- Frequent co-mutation in BRAF fusion-positive colorectal cancers (along with RNF43, KMT2D, and ARID1A); identified in a tumor-agnostic cohort of 833 patients across 52 histologies PMID:38922339.
- Identified as a shared putative oncogenic mutation in an exceptional responder case of MSI-H/dMMR prostate cancer; clonal relatedness confirmed across serial tumor samples PMID:38949888.
- Mismatch-repair gene mutated in hypermutated colorectal tumors in the 276-tumor TCGA CRC cohort PMID:22810696
- Co-mutated with MSH6 in the most hypermutated MSI-positive esophageal adenocarcinoma (EAC) case in the 149-tumor Broad WES cohort; this MSI-positive case was excluded from significance analysis PMID:23525077
- Somatic mutation in ACINAR01 (MSI-H) and other pancreatic acinar cell carcinomas; pathogenic significance unclear PMID:24293293
- Heterozygous variant of uncertain significance (VUS) in PanNET patient PN1; MSI-stable prediction by MSIsensor PMID:24326773
Cancer types (linked)
- Colorectal cancer (BRAF fusion-positive) — frequent co-mutation; may contribute to the MMR-deficient phenotype observed in some BRAF fusion-driven CRCs PMID:38922339.
- Prostate cancer (MSI-H/dMMR) — clonal MSH3 mutation in an exceptional ICB responder PMID:38949888.
Co-occurrence and mutual exclusivity
- Co-mutates with RNF43, KMT2D, and ARID1A in BRAF fusion-positive colorectal cancer PMID:38922339.
- Co-mutates with ASXL1 in the MSI-H prostate cancer exceptional responder case PMID:38949888.
Therapeutic relevance
- MSH3 co-mutation in BRAF fusion-positive CRC may indicate MMR deficiency and thus potential sensitivity to immune checkpoint blockade.
- Clonal MSH3 mutation in MSI-H prostate cancer associated with durable ICB response PMID:38949888.
Open questions
- Whether MSH3 mutations in BRAF fusion-positive CRC are a cause or consequence of the MMR-deficient phenotype is not resolved.
Sources
This page was processed by crosslinker on 2026-05-09. - PMID:22810696
This page was processed by crosslinker on 2026-05-09. - PMID:23525077
This page was processed by crosslinker on 2026-05-09. - PMID:24293293
This page was processed by crosslinker on 2026-05-09. - PMID:24326773
This page was processed by crosslinker on 2026-05-09.